Navigation Links
Pinpointing genes that control breast cancer key in finding treatments
Date:9/20/2012

EAST LANSING, Mich. As scientists continue to map breast cancer's complex genetic makeup, research at Michigan State University could lead to better diagnoses and new treatment targets.

Eran Andrechek in the Department of Physiology has been awarded a $1.5 million National Cancer Institute grant to understand why when a gene known as a transcription factor is removed from a certain type of breast cancer, tumors are delayed and the cancer's ability to spread is vastly reduced.

In about 25-30 percent of all breast cancer cases, a gene known as HER2 is "turned on," or amplified. But given that Herceptin, the most widely used drug to treat HER2 breast cancer, is effective in at most half of these patients, researchers are on the hunt for new treatments.

Andrechek is zeroing in on the E2F family of transcription factors genes that control when other genes are turned "on" or "off."

"When we look at human breast cancer patients, specifically HER2 patients, we can split them up in various groups: Some have good prognosis and respond to treatment and others don't," he said. "We need to understand why that happens.

Down the line, this type of research can have an impact on how we diagnose breast cancer and hopefully lead to better treatments."

Using bioinformatics, or computer technology applied to biological data, Andrechek and his team have shown the E2F transcription factor is active in HER2 cancers, and when it is not active, the cancer's ability to spread is vastly reduced. With the new grant, the next steps are:

  • To completely characterize the effects of removing E2F from a mouse model of HER2 cancer.
  • Determine how the changes occur once the E2F gene is removed.
  • Explore if those same mechanisms are the same in human breast cancer cases

"Since drugs such as Herceptin are only effective in 50 percent of HER2 patients, we need to know if the E2F gene is responsible for that," Andrechek said. "Given the survival differences within patients with HER2 breast cancer, there is a compelling need to understand the genetic makeup of those tumors."


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Related medicine news :

1. Researchers ID Genes That May Determine Mental Illness
2. 2 repressor genes identified as essential for placental development
3. Genes Associated With Autism Also Related to Schizophrenia
4. Genes Might Cause Some to Shun Pork
5. Blond Genes May Vary Around the World
6. Mystery of the missing breast cancer genes
7. Living longer - variability in infection-fighting genes can be a boon for male survival
8. Genes Might Be Key to Parkinsons Spread
9. Strategy discovered to activate genes that suppress tumors and inhibit cancer
10. Study Ties Genes to Lower Urinary Tract Symptoms, Prostate Cancer Risk
11. Obesity genes may influence food choices, eating patterns
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pinpointing genes that control breast cancer key in finding treatments
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: